Company Overview and News

Metminco launches bigger rights issue amid strategy shift and board changes

Metminco Limited (LON:MNC) (ASX:MNC) said it is now seeking to raise A$5.7mln through a revised rights issue as it shifts its strategy and has named a new executive chairman.
Upvote Downvote

Navarre Minerals starts major drilling program in quest for Victorian gold

Navarre Minerals Limited (ASX:NML) has started a major drilling program targeting gold at five projects in central and western Victoria.
Upvote Downvote

Navarre Minerals locates new gold structure at the Irvine project

Navarre Minerals Limited (ASX:NML) has discovered a new gold-bearing quartz-sulphide lode structure at the Cullings Prospect within its Irvine gold project in Victoria.
Upvote Downvote

Navarre Minerals to lift cash balance for Victorian gold

Navarre Minerals Ltd (ASX:NML) recently commenced the next phase of drilling at its Irvine Gold Project in Victoria.
Upvote Downvote

Navarre Minerals commences gold drilling in Victoria

Navarre Minerals Limited’s (ASX:NML) shares were trading circa 4% higher intra-day after commencing a new phase of drilling at its Irvine Gold Project in Victoria.
Upvote Downvote

Catalyst Metals hits high-grade gold at Tandarra Gold Project

Catalyst Metals (ASX:CYL) has intersected shallow high-grade gold at the Tomorrow Gold Zone, part of the Tandarra Gold Project in Victoria.
Upvote Downvote

Contact Gold Corp. Completes Business Combination and Acquisition of Carlin Trend Properties in Nevada

2017-06-08 marketwired
Contact Gold Corp. (the "Company" or "Contact Gold"), formerly Winwell Ventures Inc. ("Winwell"), is pleased to announce the completion of the previously announced business combination with Carlin Opportunities Inc. ("Carlin") by way of a court approved statutory plan of arrangement (the "Plan of Arrangement") under the Business Corporations Act (British Columbia) and the subsequent acquisition of a portfolio of 2,762 unpatented mining claims (the "Carlin Trend Properties") distributed over 13 gold properties, including the Pony Creek gold project, located in Nevada (collectively, the "Transactions").
Upvote Downvote

Navarre Minerals shares rise on drilling high-grade gold

Navarre Minerals (ASX:NML) intersected high-grade primary gold mineralisation from the maiden diamond drilling program at its Irvine Gold Project in Western Victoria.
Upvote Downvote

Navarre Minerals to begin drilling for Stawell-style gold orebodies

Navarre Minerals (ASX:NML) is commencing a 3,000 metre diamond drilling program at its Stawell Corridor Gold Project, located 15 kilometres south of Stawell in western Victoria.
Upvote Downvote

Navarre Minerals Ltd gets ready to raise

Navarre Minerals Ltd (ASX:NML) has been granted a trading halt by the ASX this morning, pending details of a capital raising.
Upvote Downvote

Navarre Minerals Ltd heads to market

Navarre Minerals Ltd (ASX:NML) has been granted a trading halt by the ASX this morning, pending details of a capital raising. The halt will remain in place until the opening of trade on Thursday 25th August 2016, or earlier if an announcement is made to the market.
Upvote Downvote


Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...